Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
DNA pharmaceuticals [[electronic resource] ] : formulation and delivery in gene therapy, DNA vaccination and immunotherapy / / edited by Martin Schleef
| DNA pharmaceuticals [[electronic resource] ] : formulation and delivery in gene therapy, DNA vaccination and immunotherapy / / edited by Martin Schleef |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2005 |
| Descrizione fisica | 1 online resource (277 p.) |
| Disciplina |
615.372
616.0796 |
| Altri autori (Persone) | SchleefM (Martin) |
| Soggetto topico |
DNA vaccines
Gene therapy Immunotherapy |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-85409-X
9786610854097 3-527-60753-6 3-527-60700-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
DNA Pharmaceuticals; Preface; Contents; List of Contributors; Abbreviations; 1 DNA Vaccines - An Overview; 1.1 Rationale for DNA Vaccines; 1.2 Preclinical Proof of Concept; 1.3 Clinical Trials; 1.4 Second-Generation Vaccines; 1.5 Conclusions; References; 2 DNA as a Pharmaceutical - Regulatory Aspects; 2.1 Introduction; 2.2 Quality Requirements for DNA used as a Gene Therapy Product; 2.2.1 Introduction; 2.2.2 Production and Purification; 2.2.2.1 Raw Materials; 2.2.2.2 Antibiotics; 2.2.2.3 Solvents; 2.2.2.4 Fermentation; 2.2.2.5 Purification; 2.2.3 Cell Banking System Procedures
2.2.3.1 Generation and Characterization of Master and Working Cell Banks2.2.4 Product Characterization and Quality Criteria; 2.2.4.1 Identity; 2.2.4.2 Purity; 2.2.4.3 Adventitious Agents; 2.2.4.4 Potency; 2.3 Safety Studies for Clinical Trials; 2.3.1 General Considerations; 2.3.2 Conduct of Preclinical Safety Studies; 2.3.2.1 Regulations; 2.3.2.2 Design of an Appropriate Toxicology Program; 2.3.2.3 Single- and Repeat-Dose Toxicity Studies; 2.3.2.4 Safety of the Formulated Plasmid DNA; 2.3.2.5 Specific Safety Considerations; 2.3.2.6 Choice of Animal Model; 2.4 Special Issues 2.4.1 Comparability of Plasmid Gene Therapy Products2.4.2 Mixed Plasmid Preparations; 2.4.3 Plasmid Molecular Structure; 2.5 Biosafety Issues and Environmental Risk Assessment; References; 3 From Bulk to Delivery: Plasmid Manufacturing and Storage; 3.1 Introduction; 3.1.1 Gene Therapy; 3.1.2 DNA Vaccination; 3.2 Manufacturing of Plasmid DNA; 3.2.1 Bacterial Cultivation; 3.2.2 Plasmid DNA Purification; 3.2.3 Innovative Aspects in Plasmid Manufacturing; 3.3 Quality Control of Plasmid DNA Vectors; 3.3.1 Proteins, Ribonucleic Acid, and Lipopolysaccharides; 3.3.2 Chromosomal DNA 3.3.3 Plasmid Identity3.3.4 Plasmid Topology (Structural Homogeneity); 3.4 Plasmid Stability during Storage and Application; 3.4.1 Long-Term Stability of Plasmid DNA; 3.4.2 Lyophilization for Long-Term Storage; 3.4.3 Stability during Application; 3.5 Future Developments; References; 4 Minimized, CpG-Depleted, and Methylated DNA Vectors: Towards Perfection in Nonviral Gene Therapy; 4.1 Introduction; 4.2 The Mammalian Immune System as a Barrier to Nonviral Gene Delivery; 4.3 Strategies to Minimize DNA Vectors 4.3.1 Excision of a DNA Fragment Containing a Transgene Expression Cassette from Plasmid DNA4.3.2 Intramolecular Site-Specific Recombination Within a Bacterial Plasmid; 4.3.3 Synthesis of Minimized DNA Vectors by PCR; 4.3.4 Improvement of Minimized DNA Vector Yield and Purity; 4.4 Depletion of CpG Dinucleotides in the Bacterial Vector Backbone; 4.5 Methylation of CpG Dinucleotides in Plasmid DNA; 4.6 Towards an Ideal Nonviral Vector; 4.7 Conclusion; References; 5 Localized Nucleic Acid Delivery: A Discussion of Selected Methods; 5.1 Foreword; 5.2 Nucleic Acid Delivery - What For? 5.3 Nucleic Acid Delivery - How? |
| Record Nr. | UNINA-9910144557003321 |
| Weinheim, : Wiley-VCH, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
DNA pharmaceuticals [[electronic resource] ] : formulation and delivery in gene therapy, DNA vaccination and immunotherapy / / edited by Martin Schleef
| DNA pharmaceuticals [[electronic resource] ] : formulation and delivery in gene therapy, DNA vaccination and immunotherapy / / edited by Martin Schleef |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2005 |
| Descrizione fisica | 1 online resource (277 p.) |
| Disciplina |
615.372
616.0796 |
| Altri autori (Persone) | SchleefM (Martin) |
| Soggetto topico |
DNA vaccines
Gene therapy Immunotherapy |
| ISBN |
1-280-85409-X
9786610854097 3-527-60753-6 3-527-60700-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
DNA Pharmaceuticals; Preface; Contents; List of Contributors; Abbreviations; 1 DNA Vaccines - An Overview; 1.1 Rationale for DNA Vaccines; 1.2 Preclinical Proof of Concept; 1.3 Clinical Trials; 1.4 Second-Generation Vaccines; 1.5 Conclusions; References; 2 DNA as a Pharmaceutical - Regulatory Aspects; 2.1 Introduction; 2.2 Quality Requirements for DNA used as a Gene Therapy Product; 2.2.1 Introduction; 2.2.2 Production and Purification; 2.2.2.1 Raw Materials; 2.2.2.2 Antibiotics; 2.2.2.3 Solvents; 2.2.2.4 Fermentation; 2.2.2.5 Purification; 2.2.3 Cell Banking System Procedures
2.2.3.1 Generation and Characterization of Master and Working Cell Banks2.2.4 Product Characterization and Quality Criteria; 2.2.4.1 Identity; 2.2.4.2 Purity; 2.2.4.3 Adventitious Agents; 2.2.4.4 Potency; 2.3 Safety Studies for Clinical Trials; 2.3.1 General Considerations; 2.3.2 Conduct of Preclinical Safety Studies; 2.3.2.1 Regulations; 2.3.2.2 Design of an Appropriate Toxicology Program; 2.3.2.3 Single- and Repeat-Dose Toxicity Studies; 2.3.2.4 Safety of the Formulated Plasmid DNA; 2.3.2.5 Specific Safety Considerations; 2.3.2.6 Choice of Animal Model; 2.4 Special Issues 2.4.1 Comparability of Plasmid Gene Therapy Products2.4.2 Mixed Plasmid Preparations; 2.4.3 Plasmid Molecular Structure; 2.5 Biosafety Issues and Environmental Risk Assessment; References; 3 From Bulk to Delivery: Plasmid Manufacturing and Storage; 3.1 Introduction; 3.1.1 Gene Therapy; 3.1.2 DNA Vaccination; 3.2 Manufacturing of Plasmid DNA; 3.2.1 Bacterial Cultivation; 3.2.2 Plasmid DNA Purification; 3.2.3 Innovative Aspects in Plasmid Manufacturing; 3.3 Quality Control of Plasmid DNA Vectors; 3.3.1 Proteins, Ribonucleic Acid, and Lipopolysaccharides; 3.3.2 Chromosomal DNA 3.3.3 Plasmid Identity3.3.4 Plasmid Topology (Structural Homogeneity); 3.4 Plasmid Stability during Storage and Application; 3.4.1 Long-Term Stability of Plasmid DNA; 3.4.2 Lyophilization for Long-Term Storage; 3.4.3 Stability during Application; 3.5 Future Developments; References; 4 Minimized, CpG-Depleted, and Methylated DNA Vectors: Towards Perfection in Nonviral Gene Therapy; 4.1 Introduction; 4.2 The Mammalian Immune System as a Barrier to Nonviral Gene Delivery; 4.3 Strategies to Minimize DNA Vectors 4.3.1 Excision of a DNA Fragment Containing a Transgene Expression Cassette from Plasmid DNA4.3.2 Intramolecular Site-Specific Recombination Within a Bacterial Plasmid; 4.3.3 Synthesis of Minimized DNA Vectors by PCR; 4.3.4 Improvement of Minimized DNA Vector Yield and Purity; 4.4 Depletion of CpG Dinucleotides in the Bacterial Vector Backbone; 4.5 Methylation of CpG Dinucleotides in Plasmid DNA; 4.6 Towards an Ideal Nonviral Vector; 4.7 Conclusion; References; 5 Localized Nucleic Acid Delivery: A Discussion of Selected Methods; 5.1 Foreword; 5.2 Nucleic Acid Delivery - What For? 5.3 Nucleic Acid Delivery - How? |
| Record Nr. | UNINA-9910829843803321 |
| Weinheim, : Wiley-VCH, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
DNA pharmaceuticals : formulation and delivery in gene therapy, DNA vaccination and immunotherapy / / edited by Martin Schleef
| DNA pharmaceuticals : formulation and delivery in gene therapy, DNA vaccination and immunotherapy / / edited by Martin Schleef |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2005 |
| Descrizione fisica | 1 online resource (277 p.) |
| Disciplina | 616.07/96 |
| Altri autori (Persone) | SchleefM (Martin) |
| Soggetto topico |
DNA vaccines
Gene therapy Immunotherapy |
| ISBN |
1-280-85409-X
9786610854097 3-527-60753-6 3-527-60700-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
DNA Pharmaceuticals; Preface; Contents; List of Contributors; Abbreviations; 1 DNA Vaccines - An Overview; 1.1 Rationale for DNA Vaccines; 1.2 Preclinical Proof of Concept; 1.3 Clinical Trials; 1.4 Second-Generation Vaccines; 1.5 Conclusions; References; 2 DNA as a Pharmaceutical - Regulatory Aspects; 2.1 Introduction; 2.2 Quality Requirements for DNA used as a Gene Therapy Product; 2.2.1 Introduction; 2.2.2 Production and Purification; 2.2.2.1 Raw Materials; 2.2.2.2 Antibiotics; 2.2.2.3 Solvents; 2.2.2.4 Fermentation; 2.2.2.5 Purification; 2.2.3 Cell Banking System Procedures
2.2.3.1 Generation and Characterization of Master and Working Cell Banks2.2.4 Product Characterization and Quality Criteria; 2.2.4.1 Identity; 2.2.4.2 Purity; 2.2.4.3 Adventitious Agents; 2.2.4.4 Potency; 2.3 Safety Studies for Clinical Trials; 2.3.1 General Considerations; 2.3.2 Conduct of Preclinical Safety Studies; 2.3.2.1 Regulations; 2.3.2.2 Design of an Appropriate Toxicology Program; 2.3.2.3 Single- and Repeat-Dose Toxicity Studies; 2.3.2.4 Safety of the Formulated Plasmid DNA; 2.3.2.5 Specific Safety Considerations; 2.3.2.6 Choice of Animal Model; 2.4 Special Issues 2.4.1 Comparability of Plasmid Gene Therapy Products2.4.2 Mixed Plasmid Preparations; 2.4.3 Plasmid Molecular Structure; 2.5 Biosafety Issues and Environmental Risk Assessment; References; 3 From Bulk to Delivery: Plasmid Manufacturing and Storage; 3.1 Introduction; 3.1.1 Gene Therapy; 3.1.2 DNA Vaccination; 3.2 Manufacturing of Plasmid DNA; 3.2.1 Bacterial Cultivation; 3.2.2 Plasmid DNA Purification; 3.2.3 Innovative Aspects in Plasmid Manufacturing; 3.3 Quality Control of Plasmid DNA Vectors; 3.3.1 Proteins, Ribonucleic Acid, and Lipopolysaccharides; 3.3.2 Chromosomal DNA 3.3.3 Plasmid Identity3.3.4 Plasmid Topology (Structural Homogeneity); 3.4 Plasmid Stability during Storage and Application; 3.4.1 Long-Term Stability of Plasmid DNA; 3.4.2 Lyophilization for Long-Term Storage; 3.4.3 Stability during Application; 3.5 Future Developments; References; 4 Minimized, CpG-Depleted, and Methylated DNA Vectors: Towards Perfection in Nonviral Gene Therapy; 4.1 Introduction; 4.2 The Mammalian Immune System as a Barrier to Nonviral Gene Delivery; 4.3 Strategies to Minimize DNA Vectors 4.3.1 Excision of a DNA Fragment Containing a Transgene Expression Cassette from Plasmid DNA4.3.2 Intramolecular Site-Specific Recombination Within a Bacterial Plasmid; 4.3.3 Synthesis of Minimized DNA Vectors by PCR; 4.3.4 Improvement of Minimized DNA Vector Yield and Purity; 4.4 Depletion of CpG Dinucleotides in the Bacterial Vector Backbone; 4.5 Methylation of CpG Dinucleotides in Plasmid DNA; 4.6 Towards an Ideal Nonviral Vector; 4.7 Conclusion; References; 5 Localized Nucleic Acid Delivery: A Discussion of Selected Methods; 5.1 Foreword; 5.2 Nucleic Acid Delivery - What For? 5.3 Nucleic Acid Delivery - How? |
| Record Nr. | UNINA-9910876820303321 |
| Weinheim, : Wiley-VCH, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
DNA vaccine technology ... annual report
| DNA vaccine technology ... annual report |
| Pubbl/distr/stampa | Washington, D.C., : U.S. Dept. of Agriculture, Agricultural Research Service |
| Descrizione fisica | : HTML files |
| Disciplina | 636 |
| Soggetto topico |
Avian influenza - Vaccination - United States
DNA vaccines - United States DNA vaccines |
| Soggetto genere / forma | Periodicals. |
| ISSN | 1948-3775 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910698668003321 |
| Washington, D.C., : U.S. Dept. of Agriculture, Agricultural Research Service | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
DNA vaccines [[electronic resource] ] : types, advantages and limitations / / Erin C. Donnelly and Arthur M. Dixon, editors
| DNA vaccines [[electronic resource] ] : types, advantages and limitations / / Erin C. Donnelly and Arthur M. Dixon, editors |
| Pubbl/distr/stampa | Hauppauge, N.Y., : Nova Science, c2011 |
| Descrizione fisica | 1 online resource (214 p.) |
| Disciplina | 615/.372 |
| Altri autori (Persone) |
DonnellyErin C
DixonArthur M |
| Collana | Immunology and immune system disorders |
| Soggetto topico | DNA vaccines |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-62081-045-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910461198203321 |
| Hauppauge, N.Y., : Nova Science, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
DNA vaccines [[electronic resource] ] : types, advantages and limitations / / Erin C. Donnelly and Arthur M. Dixon, editors
| DNA vaccines [[electronic resource] ] : types, advantages and limitations / / Erin C. Donnelly and Arthur M. Dixon, editors |
| Pubbl/distr/stampa | Hauppauge, N.Y., : Nova Science, c2011 |
| Descrizione fisica | 1 online resource (214 p.) |
| Disciplina | 615/.372 |
| Altri autori (Persone) |
DonnellyErin C
DixonArthur M |
| Collana | Immunology and immune system disorders |
| Soggetto topico | DNA vaccines |
| ISBN | 1-62081-045-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910790191703321 |
| Hauppauge, N.Y., : Nova Science, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
DNA vaccines [[electronic resource] ] : types, advantages and limitations / / Erin C. Donnelly and Arthur M. Dixon, editors
| DNA vaccines [[electronic resource] ] : types, advantages and limitations / / Erin C. Donnelly and Arthur M. Dixon, editors |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hauppauge, N.Y., : Nova Science, c2011 |
| Descrizione fisica | 1 online resource (214 p.) |
| Disciplina | 615/.372 |
| Altri autori (Persone) |
DonnellyErin C
DixonArthur M |
| Collana | Immunology and immune system disorders |
| Soggetto topico | DNA vaccines |
| ISBN | 1-62081-045-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- DNA VACCINES: TYPES, ADVANTAGES AND LIMITATIONS -- DNA VACCINES: TYPES, ADVANTAGES AND LIMITATIONS -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Chapter I Novel Carrier Adjuvant for DNA Vaccination -- Abstract -- 1. Introduction -- 2. Immunology of DNA Vaccines: Mode of Action and Immune Response Induction -- 3. Barriers in DNA Vaccine Delivery and Possible Modes to Overcome these Barriers -- 4. Novel Strategies for DNA Delivery -- 4.1. Lipid Based Carrier Adjuvants for DNA Vaccination -- 4.1.1. Liposomes -- 4.1.2. Virosomes -- 4.2. Polymers and Polymeric Carriers Systems -- 4.2.1. Polyethylenimine -- 4.2.2. Polylysine -- 4.2.3. Chitosan -- 4.2.4. Dendrimers -- 4.2.5. Poly (Lactide-Co-Glycolide) (PLG) -- 5. Concluding Remark and Future Prospects -- References -- Chapter II Improving the Immunogenicity of DNA Vaccines: A Nano-Sized Task? -- Abstract -- Introduction -- Improving Immunogenicity of Plasmid DNA Vaccines -- Routes of Delivery of Plasmid DNA Vaccines -- Physical Delivery Systems of Plasmid DNA Vaccines -- Needle-Free Delivery Methods -- Expression Optimization -- Cytokines -- Delivery Vectors for DNA Vaccines -- Bacterial Vectors -- Viral Vectors -- DNA and RNA Replicons -- Nano-Sized Vehicles for Gene Delivery -- Inorganic to Biomaterial - Past to Future -- Size Determines the Fate of Particles -- Conclusion -- References -- Chapter III Novel Delivery Strategies for DNA -- Abstract -- I. Introduction -- II. Optimization of Immunogenicity of DNA Vaccines -- 2.1. Choice of Targets and Expression Plasmid for DNA Vaccines -- 2.2. Selection of High Expression Plasmids for DNA Vaccines -- 2.3. Codon Optimization for Higher Gene Expression -- 2.4. Adjuvant Choice for DNA Vaccines -- III. DNA Delivery Strategies -- 3.1. Invasive Delivery -- 3.1.1. Needle Injection.
3.1.2. In Vivo Electroporation -- 3.1.3. Tattoo Gun Delivery -- 3.2. Non-Invasive Topical Delivery Method -- 3.2.1. Tape Stripping -- 3.2.2. Nanopatch Delivery -- 3.2.3. Nano-Particle Mediated Delivery -- 3.3. Viral-Mediated DNA Delivery Systems -- 3.4. Non-Viral Gene Delivery Systems -- 3.5. Novel Delivery Methods -- 3.5.1. Laser Mediated Delivery -- 3.5.2. Ultrasound Mediated Delivery System -- III. Future Directions -- References -- Chapter IV Recent Advances in DNA Vaccines -- Abstract -- Introduction -- DNA Vaccines X Traditional Vaccine Approaches -- Components of a DNA Vaccine -- How DNA Vaccines Work -- Delivery Methods -- Advantages X Limitations -- Strategies to Enhance Immunogenicity of DNA Vaccines -- Modifications of Plasmid Basic Design -- Delivery Methods -- Target to Dendritic Cells -- Improved Immunization Protocols -- Adjuvants -- Conclusion -- References -- Chapter V Co-Administration of Gamma Interferon Gene with DNA Vaccine Expressing Duck Hepatitis B Virus (DHBV) Proteins Enhances Therapeutic Efficacy of DNA-Based Immunization in Chronic Virus Carriers -- Abstract -- Introduction -- Materials and Methods -- Animals -- DNA Immunization -- Analysis of Viral DNA -- Analysis of Infectivity of Liver Extracts Collected from Resolved Ducks -- Histopathological and Immuno-Histochemical Analysis -- Statistical Analysis -- Results -- Decrease in Viremia following Co-Immunization with Cytokine Expressing Plasmids -- Enhancement of DHBV DNA clearance by Co-Immunization with IFN- expressing Plasmid -- Virological Analysis and Infectivity of Liver Samples Collected from Resolved Animals -- Adverse Effects of Therapy -- Conclusion -- Acknowledgments -- References -- Chapter VI The Role of DNA-IL-12 Vaccination in Eosinophilic Inflammation: A Review -- Abstract -- Basic DNA Vaccine Concepts -- Strategies for DNA Vaccine Administration. Structure and Function of Interleukin-12 -- IL-12 Therapy -- Eosinophilia and Asthma -- Impact of pcDNA-IL-12 Administration on Eosinophilia and Pulmonary Hyperreactivity in a Murine Model -- References -- Chapter VII Cured By DNA-Genetic Immunization in the Therapeutic Sector -- Abstract -- Introduction -- Modulation of the Immune System -- The Big Four - Cancer, HIV, Hepatitis and Tuberculosis -- Cancer -- HIV -- Hepatitis -- Tuberculosis -- Clinical Trials -- Safety Issues, Limitations and Disadvantages -- Conclusion -- References -- Chapter VIII DNA Vaccination against Herpesvirus -- Abstract -- Introduction -- Bovine Herpesvirus-1 -- DNA Vaccine against Bovine Herpesvirus-1 -- Route of Immunization -- Chemical Adjuvants -- Animal Response Following -- DNA Vaccination -- References -- Chapter IX DNA Vaccination: Progress and Challenges -- Abstract -- Abbreviations -- Introduction -- Advantages of DNA Vaccines -- Limitations of DNA Vaccines -- Conclusion -- Acknowledgments -- References -- Index. |
| Record Nr. | UNINA-9910825809303321 |
| Hauppauge, N.Y., : Nova Science, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Genetic vaccines and therapy
| Genetic vaccines and therapy |
| Pubbl/distr/stampa | [London], : BioMed Central, 2003- |
| Descrizione fisica | 1 online resource |
| Soggetto topico |
DNA vaccines
Gene therapy Vaccines, DNA Genetic Therapy Gene Therapy |
| Soggetto genere / forma |
Periodicals.
Periodical |
| Soggetto non controllato | Microbiology & Immunology |
| ISSN | 1479-0556 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-996212786403316 |
| [London], : BioMed Central, 2003- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Genetic vaccines and therapy
| Genetic vaccines and therapy |
| Pubbl/distr/stampa | [London], : BioMed Central, 2003- |
| Descrizione fisica | 1 online resource |
| Soggetto topico |
DNA vaccines
Gene therapy Vaccines, DNA Genetic Therapy Teràpia genètica Vacunes |
| Soggetto genere / forma |
Periodicals.
Periodical Revistes electròniques. |
| ISSN | 1479-0556 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910142912703321 |
| [London], : BioMed Central, 2003- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Plasmids for therapy and vaccination [[electronic resource] /] / edited by M. Schleef
| Plasmids for therapy and vaccination [[electronic resource] /] / edited by M. Schleef |
| Pubbl/distr/stampa | Weinheim ; ; New York, : Wiley-VCH, c2001 |
| Descrizione fisica | 1 online resource (308 p.) |
| Disciplina |
615.32
615.372 |
| Altri autori (Persone) | SchleefM (Martin) |
| Soggetto topico |
DNA vaccines
Gene therapy Plasmids |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-281-76398-5
9786611763985 3-527-61283-1 3-527-61284-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Plasmids for Therapy and Vaccination; Preface; Contents; List of Contributors; 1 The Biology of Plasmids; 1 Introduction: What are plasmids?; 2 General properties of plasmids; 2.1 Plasmid replication and its control; 2.2 The molecular basis of incompatibility; 2.3 Plasmid inheritance; 2.4 Mechanisms of plasmid spread; 2.4.1 Conjugation in gram-negative bacteria; 2.4.2 Conjugation in gram-positive bacteria; 3 Plasmid-encoded phenotypes; 3.1 Bacteriocin production and resistance; 3.2 The Ti plasmids; 3.3 Heavy metal resistance; 3.4 Other phenotypical traits
4 The clinical importance of plasmids4.1 The spread of antibiotic resistance and the evolution of multiple antibiotic resistance; 4.2 Transfer of antibiotic resistance genes; 4.3 Mechanisms of antibiotic resistance; 4.4 Bacterial virulence genes; 5 Plasmid cloning vectors; 6 Perspectives; References; 2 Structures of Plasmid DNA; 1 Introduction; 2 Topological structures of plasmids; 3 Supercoiling of DNA; 4 DNA intercalating dyes; 5 Analysis of plasmid structures; 5.1 Electron microscopy (EM); 5.2 Agarose gel electrophoresis (AGE); 5.3 Capillary gel electrophoresis (CGE) 5.4 Analytical chromatography6 Conclusion; References; 3 Genetic Vaccination with Plasmid Vectors; 1 Introduction; 2 Vector design; 2.1 Plasmid DNA; 2.2 Construction of simple transcription units; 2.3 Construction of complex transcription units; 3 Strategies for DNA delivery; 4 Priming humoral and cellular immune responses by DNA vaccines; 5 Experimental strategies facilitated by DNA vaccination; 6 Unique advantages of DNA vaccination; 7 DNA vaccines in preclinical animal models; 7.1 DNA vaccines to control infectious diseases; 7.2 Therapeutic tumor vaccines; 7.3 Autoimmune disease 7.4 Treatment of allergy by therapeutic DNA vaccination8 Proposed clinical applications of DNA vaccines; 9 Risks of nucleic acid vaccination; 10 Future perspectives; References; 4 A Liposomal iNOS-Gene Therapy Approach to Prevent Neointimal Lesion Formation in Porcine Femoral Arteries; 1 Introduction; 2 Results and discussion; 2.1 Therapeutic plasmid; 2.2 The gene therapy product has a clinically acceptable format; 2.3 Efficient gene transfer was established in a minipig femoral artery injury model; 2.4 Transfection efficiency is dose dependent 2.5 Non-viral iNOS gene transfer efficiently inhibits neointimal lesion formation3 Summary and perspectives; References; 5 lmmunotherapy of Chronic Hepatitis B by pCMV-S2.S DNA Vaccine; 1 Introduction; 1.1 Hepatitis B: the disease; 1.2 Hepatitis B: treatments; 1.3 Hepatitis B: immune response to infection; 1.4 What are DNA vaccines?; 1.5 Which DNA vaccines for hepatitis B?; 2 DNA vaccines for the prevention of hepatitis B; 2.1 The mouse model; 2.1.1 Humoral response; 2.1.2 Cell-mediated response; 2.1.3 Mechanisms of DNA-induced immune response to HBsAg; 2.1.4 The primate model 2.1.5 DNA-based vaccination of chimpanzees against HBV |
| Record Nr. | UNINA-9910144561703321 |
| Weinheim ; ; New York, : Wiley-VCH, c2001 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
DNA vaccines
(12)
- Gene therapy (8)
- Immunotherapy (3)
- Plasmids (3)
- Genetic Therapy (2)